Dailypharm Live Search Close

¡èSales of local subsidiaries in Japan & Southeast Asia

By Kim, Jin-Gu | translator Choi HeeYoung

21.03.23 12:30:22

°¡³ª´Ù¶ó 0
¡éSales of Beijing Hanmi and Yangzhou Ilyang


While the earnings of subsidiaries in China and North America, which were relatively affected by COVID-19, decreased significantly, the performance of local subsidiaries in Japan and Southeast Asia increased relatively.
¡ß¡é20% sales of Beijing Hanmi / ¡é13%, Ilyang / ¡é12%, China

According to the Financial Supervisory Service on the 23rd, the total sales of 24 local subsidiaries in China last year was ₩453.9 billion won. It decreased by 13% from ¡é519.7 billion in 2019. During the same period, net income decreased by 17% from ₩58.8 billion to ₩48.8 billion.

It is an analysis that it was directly affected by COVID-19 crisis. China has implemented a strong co

Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)